This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Endocrine/metabolic disease				
Diabetes	Histone deacetylase 3 (HDAC3)	<p>A study in cell culture suggests inhibiting HDAC3 could help treat type 1 diabetes. In a rat β cell line, knockdown of Hdac3 decreased activation of caspase-3 (Casp3; Cpp32), a mediator of type 1 diabetes-associated apoptosis, compared with no knockdown. Next steps include developing selective HDAC3 inhibitors to test in cellular and mouse models of diabetes.</p> <p>Repligen Corp.'s RG2833, a selective HDAC3 inhibitor, is in Phase I testing in ataxia.</p> <p>SciBX 5(27); doi:10.1038/scibx.2012.704 Published online July 12, 2012</p>	Unpatented; licensing status not applicable	<p>Chou, D.H.-C. <i>et al. Chem. Biol.</i>; published online June 22, 2012; doi:10.1016/j.chembiol.2012.05.010 Contact: Bridget K. Wagner, Broad Institute of MIT and Harvard, Cambridge, Mass. e-mail: bwagner@broadinstitute.org</p>